financetom
Business
financetom
/
Business
/
Sezzle Insider Sold Shares Worth $1,289,841, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sezzle Insider Sold Shares Worth $1,289,841, According to a Recent SEC Filing
Oct 5, 2024 5:12 AM

12:58 PM EDT, 10/04/2024 (MT Newswires) -- Paul Martin Purcell, Former Director, on October 02, 2024, sold 7,824 shares in Sezzle ( SEZL ) for $1,289,841. Following the Form 4 filing with the SEC, Purcell has control over a total of 82,776 shares of the company, with 82,776 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1662991/000186499124000062/xslF345X05/primary_doc.xml

Price: 150.37, Change: +1.77, Percent Change: +1.19

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis
May 26, 2025
05:10 PM EDT, 05/21/2025 (MT Newswires) -- Insmed ( INSM ) said Wednesday that brensocatib, its investigational dipeptidyl peptidase-1 inhibitor for non-cystic fibrosis bronchiectasis, demonstrated consistent efficacy and safety across three prespecified subgroups in the phase 3 Aspen trial. The subgroup analyses included adolescents, patients on macrolide therapy, and those with varying blood eosinophil levels. The data showed brensocatib reduced...
Walmart to cut 1,500 jobs, the Wall Street Journal reports
Walmart to cut 1,500 jobs, the Wall Street Journal reports
May 26, 2025
May 21 (Reuters) - Retail bellwether Walmart ( WMT ) plans to cut about 1,500 jobs as part of a restructuring plan to lower expenses, the Wall Street Journal reported on Wednesday, citing a person familiar with the matter. ...
Cematrix Announcing $5.7 Million in New Contract Awards
Cematrix Announcing $5.7 Million in New Contract Awards
May 26, 2025
05:08 PM EDT, 05/21/2025 (MT Newswires) -- CEMATRIX Corporation ( CTXXF ) , after trade Wednesday said it won $5.7 million in new contract awards. The cellular concrete products company noted the new contract awards include a significant contract for a tunnel grouting application, while the remaining projects are all small to mid-sized projects for light weight fill applications in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved